Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
April 26, 2017 07:00 ET
|
Heat Biologics
DURHAM, N.C., April 26, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting
April 05, 2017 08:00 ET
|
Heat Biologics
Combining ComPACT DNA electroporation and cellular vaccination led to increased tumor antigen-specific CD8+ T cells, delayed tumor progression and improved overall survival in preclinical models ...
Heat Biologics Reports Fiscal Year 2016 Financial Results
March 31, 2017 07:00 ET
|
Heat Biologics
DURHAM, N.C., March 31, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock
March 28, 2017 16:01 ET
|
Heat Biologics
DURHAM, N.C., March 28, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock
March 23, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 23, 2017 (GLOBE NEWSWIRE) -- HEAT BIOLOGICS, INC. (“HEAT”) (NASDAQ:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Proposed Public Offering of Common Stock
March 22, 2017 16:03 ET
|
Heat Biologics
DURHAM, N.C., March 22, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
March 21, 2017 07:00 ET
|
Heat Biologics
ELISPOT results suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients Tumor reduction corresponds to enhanced immune...
Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
March 16, 2017 07:02 ET
|
Heat Biologics
Grant to fund Dr. Natasa Strbo’s Zika preclinical research at the University of Miami DURHAM, N.C., March 16, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
March 13, 2017 07:00 ET
|
Heat Biologics
Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) Signs of synergistic efficacy with nivolumab enables expansion to...
Heat Biologics to Present at 29th Annual ROTH Conference
March 09, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...